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Ral Guanine nucleotide dissociation stimulator-Like 2 (RGL2) is a member of the RalGDS 
family that we have isolated and characterized as a potential effector for Ras and the Ras 
analogue Rap1b. The protein shares 89% sequence identity to its mouse orthologue Rlf. In 
this study we further characterized the G-protein binding features of RGL2 and also 
demonstrated that RGL2 has guanine nucleotide exchange activity toward the small GTPase 
RalA. We found that RGL2/Rlf properties are well conserved between human and mouse 
species. Both RGL2 and Rlf have a putative PKA phosphorylation site at the C-terminal of 
the domain that regulate the interaction with small GTPases. We demonstrated that RGL2 is 
phosphorylated by PKA and phosphorylation reduces the ability of RGL2 to bind H-Ras. As 
RGL2 and Rlf  are  unique in the RalGDS family in having a PKA site in the Ras Binding 
Domain,  these results indicate that Ras  may distinguish between the different RalGDS 
family members by their phosphorylation by PKA. 
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Ras and members of the Ras family are low molecular weight monomeric GTP binding 
proteins that act as molecular switches by coupling extracellular signals to different cellular 
responses. Signal transduction through Ras and other members of the Ras family occurs by 
reversible binding of GTP, while the inactive form of Ras is bound to GDP. Switching 
between these two states is regulated by positive and negative signals conveyed by GTP 
exchange factors (GEFs), which catalyze the exchange of GDP for GTP, and GTPase-
activating proteins (GAPs), which hydrolyze GTP. Effector molecules mediate the 
intracellular effects of Ras family proteins by interacting with the GTP-bound active form. It 
has become clear in these last two decades that Ras proteins can interact with many effector 
molecules to activate parallel pathways. The Ser/Thr kinase c-Raf-1, was identified as the 
first mammalian Ras effector, followed shortly afterwards by Ral Guanine nucleotide 
Dissociation Stimulators (RalGDSs) and phosphatidylinositol 3-kinase (PI3K) [1].  
RalGDS gene was first identified by PCR-based screening using sequences derived from 
yeast CDC25 gene, and the encoded protein was found to stimulate the dissociation of 
guanine nucleotides from the Ras family member Ral [2]. RalGDS was also identified 
independently as a binding partner for Ras in yeast two-hybrid screening [3,4]. Besides this, 
other proteins homologous to RalGDS, RGL (RalGDS like) [5], Rlf (RalGDS like factor) [6], 
RGL2 [7], and RGL3 [8,9], have been identified as binding partners for small G-proteins 
through yeast two-hybrid screening. They act as effectors in that the binding to Ras or Rap is 
GTP-dependent, but they also have a sequence that suggests they can act as exchange factors. 
Thus, they have a structure that suggests they might mediate cross-talk or amplification 
between G proteins, binding to one G protein and activating another. 
All the RalGDS family proteins contain a central CDC25 homology domain, a N-terminal 
Ras Exchange Motif (REM) [10], and a C-terminal Ras/Rap Binding Domain (RBD) 
(Fig.1A).  
The Ras binding abilities of RalGDS family proteins depend on their C-terminal region 
which is highly conserved in the family (Fig.1B). The minimal Ras Binding Domain (RBD) 
of RalGDS, RGL and Rlf  has been identified by N- and C- terminal deletion truncation 
[6,11-13], and the three-dimensional structure determined by NMR spectroscopy and/or X-
ray crystallography [14-16]. Similarities in the hydrophobicity profiles and three-dimensional 
folding between the Ras-binding domains of RalGDS family members and the Ras effector 
Raf have been noted, although the sequence identity is very low [17]. As with Raf-RBD, the 
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RBD domains of RalGDS, RGL and Rlf assume an ubiquitin-like conformation characterized 
by ββαββαβ-type tertiary structure [14-16,18]. 
The CDC25 homology domain is downstream to the REM motif (see Fig.1A). CDC25 is a 
GEF for Ras in yeast cells, where it regulates the conversion of the inactive GDP-bound form 
of Ras to the active GTP-bound form [19]. The catalytic domain is a region of about 250 
residues. Five structurally conserved regions (scr1-5) were noted in this domain by sequence 
alignment of multiple yeast and mammalian GEFs. Although the core catalytic domain of 
CDC25 is able to function as a GEF in vitro, a larger region of about 450 residues is required 
in vivo. This larger sequence encompasses an approximately 50 residue N-terminal homology 
region that has been variably described as the REM, CNC (Conserved Non Catalytic), LTE1 
homology region (after the yeast GEF, LTE1) or scr0 (being N terminal of scr1) in the 
literature; this region is required for maintaining the conformation of the catalytic CDC25 
domain [10]. Many proteins from different organisms have a CDC25 homologous domain 
that has been characterized as a GEF for different proteins of Ras family [10]. The CDC25 
homology domain of the RalGDS family proteins, RalGDS, RGL3, Rlf, acts as an exchange 
factor for Ral, a member of the Ras family [2,8,20] but a more detailed analysis of the GEF 
activity spectrum is lacking. 
RGL2 was first identified through a yeast two-hybrid screen for Rap1 binding proteins [7]. 
The full sequence of the RGL2 gene, encoding 777 aminoacids, was subsequently established 
by sequencing of a centromeric region of human chromosome 6 [21]. RGL2 shares 89% 
amino acid sequence identity in its entire protein sequence to its mouse orthologue Rlf and 
22-25% amino acid sequence identity to the other members of the family. The highest 
sequence homology between RGL2 and the other members of the family is in the three 
functional domains, REM, CDC25 and RBD. 
A C-terminal 158 amino acid fragment of RGL2 interacts specifically with Ras family 
proteins that share identical effector domain sequences with Rap1 (H-Ras, R-Ras, Tc21). The 
interaction between RGL2 C-158 is GTP-dependent and requires an intact Rap1 and H-Ras 
effector domain, thus indicating that RGL2 might be a potential effector for Ras proteins [7]. 
Furthermore, studies on NIH3T3 and A10 cells clearly indicated an involvement of RGL2 in 
cellular processes regulated by Rap1 and Ras [7,22]. 
In the present study, we further characterized the G-protein binding features of RGL2 by 
analysing the properties of its  putative functional domains. In particular, we assayed the 
ability of the N-terminal domain of RGL2 to function as exchange factor towards different 
proteins of the Ras family. We determined the minimal binding domain of RGL2 for Ras and 
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Rap1b and the critical sequences for interaction; finally we demonstrated that the Ras 
Binding Domain of RGL2 is phosphorylated by Protein Kinase A and that phosphorylation  




Two-hybrid analysis of RGL2 interaction – The different mutants of RGL2 were made by PCR 
using RGL2 (647-736) [23] as a template and then fused in-frame with the GAL4 activation domain 
in the Y2H pGAD424 vector (Clontech Laboratories Inc., Mountain View, CA) as EcoRI/BamHI 
inserts. All constructs were verified by sequencing. Expression of GAL4AD fusion proteins in yeast 
cells was verified by Western blot analysis with anti-GAL4 AD monoclonal  antibody. 
pGBT9 constructs carrying cDNAs encoding wild type and G12V, S17N, T35A and E37G mutant 
Rap1b, H-Ras(G12V), wild type RalA, RhoA and Rac1 were prepared in a previous work [7]. The 
constructs pGBT9-wild type H-Ras and pGBT9-H-Ras(T35A) were kindly provided by Linda van 
Aelst and Michael Wigler (Cold Spring Harbor Laboratories, Cold Spring Harbor, NY). 
The interaction of different fragments of RGL2 with native and mutated forms of H-Ras and Rap1b 
was assayed by a two hybrid assay as already described [7]. 
 
Expression and purification of GST-fusion proteins – The constructs pGEX-RalA and pGEX-H-
Ras were provided by Douglas Andres (University of Kentucky, College of Medicine, Kentucky, 
USA). 
RGL2(647-736), RGL2(647-706), RGL2(677-736), RGL2(262-777), RGL2(681-777), RGL2(544-
777), Rap1b, RhoA and Rac1 coding sequences were fused into the pGEX-4T-3 vector (Amersham 
Pharmacia Biotech, UK Ldt.) as BamHI-EcoRI inserts. RGL2(544-777)(S737A) was prepared by 
recombinant PCR using the wild type fragment as a template and cloned as above. RGL2(1-518) and 
RGL2(83-518) were amplified by PCR and then ligated into the pGEX-4T-1 vector via EcoRI site. 
The different fragments of RGL2 were expressed and purified as GST fusion proteins  by using the 
GST Gene Fusion System (Amersham Pharmacia Biotech ), as already described [23].  GST fusion 
proteins were finally analyzed by Western blotting with an anti-GST antibody (Amersham 
Pharmacia). The amount of expressed proteins was determined by using the Bradford method [24].  
 
Expression and purification of N-terminal His-tagged proteins – H-Ras(G12V) and 
Rap1b(G12V) cDNAs were ligated into the pET28a vector (Novagen, Madison, WI, USA) as 
BamHI-SalI inserts. The constructs were used to transform BL21(DE3) cells (Novagen). 
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Transformed cells were then grown overnight at 37°C in 2x YTG medium containing kanamycin (30 
µg/ml). The cell suspension was then diluted 1:50 with fresh 2x YTG-kan medium and incubated at 
37°C to an adsorbance of 0.6-0.8 (600 nm). After incubation, IPTG (100mM) was added to a final 
concentration of 1mM and the cells were grown for 6 hours at 30°C. Cells were then collected by 
centrifugation at 5000 xg for 20 min at 4°C, and the resulting pellet was resuspended in Lysis Buffer 
(50 mM NaH2PO4, 300 mM NaCl, 10 mM Imidazole, pH 8.0, 4 ml/g of pellet) containing protease 
inhibitors (28µM E64, 1mM PMSF, 1mM AEBSF, 10µM Pepstatine A, 10µM Leupeptin, 1mM 
Benzamidine). After incubation with Lysozyme (100 µg/ml)  for 30 min in ice, cells were frozen at   
–20°C, thawed and finally lysed by sonication. The cell lysate was centrifuged at 4°C for 30 min at 
10000 x g; the supernatant was mixed with Ni-NTA agarose according to the manufacturer’s 
instructions (Qiagen S.p.A., Milano, Italy), gently shaken at 4°C for 60 min and then loaded into a 
column. After two washing steps with buffer containing NaH2PO4 (50 mM), NaCl (300 mM), 
Imidazole (20 mM), pH 8.0, proteins were eluted 4 times with 0.5 ml of elution buffer (50 mM 
NaH2PO4, 300 mM NaCl, 250 mM Imidazole, pH 8.0). Purified proteins were analyzed as above. The 
immunodetection of N-terminal His-tagged proteins was performed by using RGS-His HRP 
conjugate antibody (Qiagen S.p.A., Milano, Italy). 
 
ELISA format binding assay – The in vitro interaction of different fragments of RGL2 with Ras 
proteins has been studied using a method described by Ghosh et al. [25]. Briefly, 50 pmoles of 
purified His-tagged H-Ras(G12V) or His-tagged Rap1b(G12V) in coating buffer (10mM Na2CO3, 
30mM NaHCO3, pH 9.6) were loaded onto the wells of a 96-well titer plate and allowed to bind 
overnight at 4°C in the presence of Gpp(NH)p (50mM) (Sigma). After a 2 hour blocking at 37°C with 
BSA (0.1%) in PBS buffer, GST-fusion proteins (test proteins) in PBS-BSA (0.1%) were added and 
incubated at 37°C for 1 hour. The plate was washed three times in PBS-Tween 20 (0.1%) and 
incubated with anti-GST antibody (1:3000 dilution) (Amersham Parmacia) for 1 hour at room 
temperature. After three washings in PBS-Tween 20 (0.1%) the plate was incubated with anti-goat 
IgG-peroxidase conjugate (Sigma, 1:25000 dilution)  for 1 hour at 37°C. Every single step of the 
assay was performed in the presence of 50 mM Gpp(NH)p. TMB was finally used as chromogen and 
the reaction blocked with H2SO4 (0.5M). The resulting absorbances were detected at 450 nm on an 
ELISA plate reader (Molecular Devices, VERSAmax tunable microplate reader). 
 
In vitro guanine nucleotide exchange reactions – GDP dissociation from several Ras family 
members in the presence or in the absence of RGL2(1-518) or RGL2(83-518) was measured using a 
method described by Shao et al. [8]. Briefly, 0.1 nmoles of the different Ras proteins fused to GST 
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were incubated with  0.1 nmoles of [3H]GDP (Amersham Pharmacia) in  50 µl of loading buffer 
containing Tris-HCl (20 mM, pH 7.5), NaCl (100 mM), EDTA (1 mM), MgCl2 (0.919 mM), DTT (1 
mM), and BSA (1 µg/µl) at 30°C for 30 min to allow  [3H]GDP loading. MgCl2 was then added to the 
incubation mixture to adjust the final MgCl2 concentration to 10 mM. Unlabeled GDP was added to 
the reaction buffer to a final concentration of  1 mM to initiate  [3H]GDP dissociation in the presence 
or in the absence of recombinant GST-RGL2(1-518) or GST-RGL2(83-518) (5 µM). The reaction 
was carried out at 20°C. At the indicated times after the addition of unlabeled GDP, reaction was 
stopped by adding to each sample 2 ml of ice-cold washing buffer (20 mM Tris-HCl, 100 mM NaCl, 
10 mM MgCl2, 1 mM DTT, pH 7.5). The samples were then filtered on nitrocellulose membrane 
(0.45 µm), washed and counted for radioactivity. 
 
In vitro phosphorylation assay - Phosphorylation of purified GST, GST-RGL2(262-777), GST-
RGL2(681-777), GST-RGL2(544-777) and its mutant S737A was obtained by incubating 20 pmol of 
each protein with the PKA catalytic subunit (0.2 U) (Sigma, St.Louis, MO, USA) for 30 min at 30°C 
in a 0.01 ml reaction mixture containing  Tris-HCl (20mM, pH 7.5), EGTA (1mM), MgCl2 (5 mM) 
and γ-[32P]ATP (0.002 mCi) (Amersham Pharmacia). The reaction was stopped by adding the same 
volume of reduced sample buffer and boiling for three minutes. The entire incubation mixtures were 
analyzed by SDS-PAGE [26] followed by autoradiography.  
For interaction studies, phosphorylated GST-RGL2(544-777) was obtained by incubating 10 pmol of 
protein with the PKA catalytic subunit (5U) for 1 hour at 30°C in a 0.01 ml reaction mixture 
containing ATP (0.1mM), Tris-HCl (20mM, pH 7.5), EGTA (1mM), and MgCl2 (5 mM). Incubation 
mixtures with GST or RGL2(544-777) without the PKA catalytic subunit were prepared as control. 
After phosphorylation, aliquots of incubation mixtures containing about 2 µg of phosphorylated or 
unphosphorylated GST-RGL2(544-777) were analyzed on a 16% polyacrylamide gel by SDS-PAGE. 
Phosphorylated protein was stained with Pro-Q Diamond phosphoprotein gel stain (Life Technology, 
Carlsbad, CA, USA) and visualized by using a Typhoon 9400 apparatus (Amersham Biosciences).  
Phosphorylated and unphosphorylated RGL2(544-777) were used in the ELISA format assay already 
described to compare their ability to bind H-Ras(G12V) and Rap1b(G12V).  
 
Phosphorylation of RGL2 in mammalian cells - Full length wild-type RGL2 (RGL2wt) and 
RGL2(S737A) coding sequences were ligated in pEGFPC2 vector (Clontech) . 
Human embryonic kidney cells (HEK293) were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) with 10% foetal bovine serum (FBS) and 1% penicillin/streptomycin at 37°C in 5% CO2. 
Cells were transfected by the calcium phosphate method with pEGFPC2-RGL2wt or pEGFPC2-
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RGL2S737A or empty vector and allowed to grow for 48 hours. Cells were serum-starved for 4 hours 
and then incubated for 30 min in the presence or in the absence of 20µM forskolin. Following drug 
treatment cells were washed twice with PBS and harvested in 0,5 ml of lysis buffer (10% v/v 
glycerol, 1% v/v NP40, 50mM Tris.HCl pH 7.4, 200mM NaCl, 2,5 mM MgCl2) containing protease 
inhibitors (1mM PMSF, 1mM AEBSF, 10µM Pepstatin A, 10µM Leupeptin, 1mM Benzamidine)  
and phosphatase inhibitors (1 mM Na3VO4, 10 mM NaF). The cell lysates were then  centrifuged 10 
min at 15000xg 4°C and supernatants were transferred to a new centrifuge tube. Protein 
concentrations were determined by the Bradford assay. GFP-fusion proteins were 
immunoprecipitated from cell protein extract with anti-GFP antibody (Abcam, Cambridge UK), and 
then analyzed by SDS-PAGE followed by ProQ Diamond gel staining. The same gel was then 
washed twice with H2O and stained with Coomassie Brilliant Blue. A second gel was run as a control 
with the same amount of proteins and analyzed by Western blotting with anti-GFP. 
 
 
RESULTS AND DISCUSSION 
 
Structure-function analysis of RGL2-RBD – We have previously shown that the smallest RGL2 
region interacting with Ras and Rap1b is a C-terminal 151 aminoacids fragment (RGL2(627-777)) 
[7]. This fragment contains a 90 amino acids region (647-736) that presents a very high homology 
with the RBDs of RalGDS family members (Fig. 1B). On the basis of this evidence, we speculated 
that RGL2(647-736) might be the domain of RGL2 directly involved in the interaction with Ras 
proteins. To test this hypothesis, we produced RGL2 deletion mutants encoding either RGL2(647-
736) fragment or the RGL2(647-706) and RGL2(677-736) shorter fragments lacking C- and N-
terminal 30 aa residues, respectively (Fig. 2A), and examined the binding of these fragments to H-
Ras and Rap1b using both a two-hybrid and an in vitro assay. As shown in Fig.2B, the RGL2(647-
736) fragment interacted in a two-hybrid assay with wild type H-Ras and Rap1b and dominant 
positive mutants of H-Ras and Rap1b with defective GTPase activity (G12V). Wild type and 
constitutively activated (G12V) mutants of Rap1b and H-Ras interacted with very similar affinity in 
the semiquantitative β-galactosidase filter assay (fig 2B). The lack of an endogenous yeast GAP 
activity for Ras and Rap [27] may explain why activating mutations did not result in higher 
interaction with the RGL2 fragment.  Rap1b(S17N), a dominant negative mutant with higher affinity 
for GDP than GTP, showed no detectable interaction with RGL2(647-736), suggesting that 
RGL2(647-736) mutant exhibits preferential binding to the active GTP-bound form of Rap1b. On the 
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other hand, no detectable interaction was observed between the RGL2(647-706) and RGL2(677-736) 
fragments and H-Ras or Rap1b in the two-hybrid assay conditions (Fig.2B).  
To further analyse the binding of RGL2 mutants to Ras/Rap, GST-fusion proteins containing the 
different fragments of RGL2 were used in an ELISA based assay [25] together with N-terminal His-
tagged H-Ras(G12V). As shown in Fig.2C, RGL2(647-736) was able to bind GTP-H-Ras(G12V), 
confirming the yeast two-hybrid results. Deletion of the highly conserved N-terminal 30 amino acids 
of RGL2(647-736) abrogated the binding to activated H-Ras; deletion of the C-terminal 30 amino 
acids reduced but did not abrogate the ability of RGL2 to associate with H-Ras in vitro. The same 
RGL2 mutant was unable to interact with Ras/Rap in the in vivo two hybrid assay (see Fig. 2B), 
suggesting that this shorter fragment, even though it is stabily expressed in yeast cells (as verified by 
Western blot analysis of GAL4AD fusion proteins, data not shown), would have difficulty in folding 
properly, thus affecting the ability to bind Ras. This evidence indicates a structural relevance of the 
C-terminal portion of the RGL2(647-736) domain. 
These results indicate that the fragment RGL2(647-736) is the minimal binding domain of RGL2 for 
Ras and Rap1b (RGL2-RBD). Our findings are in agreement with data concerning the RBDs of the 
other RalGDS family members [6,11-13] and are further supported by a three-dimensional model of 
the RGL2(647-736) region [23] showing that this portion may fold in a canonical RBD ββαββαβ-
type tertiary structure (Fig.3A). 
As shown in Fig.1B, RGL2-RBD contains many conserved residues. On the basis of the RGL2 3D 
model and taking into account what had already been demonstrated for other members of the family 
[13,18,28], we generated eight different mutants of RGL2(647-736) and assayed their interaction 
with Ras/Rap by two hybrid assay. Among conserved residues (grey residues in Fig.1B), we chose 
charged, fully solvent-exposed residues that appeared likely to interact with Ras proteins.  
As shown in Table 1, the interaction of RGL2-RBD with wild type Rap1b and H-Ras was abrogated 
by substitution of Arg653, Lys666 and Lys686 with Ala. Mutation of residues adjacent to these 
critical residues (Y665A and N687A) produced RGL2 fragments still able to interact with Ras 
proteins but with lower affinity in the semiquantitative β-galactosidase filter assay. The effects of the 
various mutations on binding to Rap1b were similar to the effects on binding to H-Ras. Substitution 
of Arg682 with Ala did not have any effect on the binding to either molecule. Substitution of Asp690 
with Ala did not abrogate the interaction with Rap1b and H-Ras; the binding to H-Ras appeared to be 
stronger than the binding to Rap1b. The RGL2-RBD(Y719A) mutant still interacted with H-Ras and 
Rap1b. 
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It has been observed previously that Lys687 in Rlf, corresponding to Lys686 in RGL2, is essential for 
Ras association [13]; here we demonstrated that Arg653 and Lys666, in addition to Lys686 are 
critical residues for the interaction of RGL2 with its target G proteins. On the basis of the predicted 
three-dimensional structure of the RGL2-RBD, the three residues are exposed at the same side of the 
RGL2 tertiary fold and located in the β1 strand, β2 strand and α1 helix, respectively (see Fig.3A). 
The reciprocal position of the three critical residues and their location in the tertiary fold of RGL2-
RBD, as well as the evidence that their absence (in the RGL2(677-736)) completely abrogated both 
in vivo and in vitro interaction, strongly support their participation in the binding event. This is all 
consistent with a requirement for positively charged residues on β1, β2 and α1, which form a 
structural epitope required for productive complex formation for Ras/Rap binding proteins [29]. As 
with Lys686, Arg682 is a positively charged, fully solvent-exposed residue of the α1 helix, but its 
substitution with Ala did not affect the interaction of RGL2 with Ras and Rap, indicating that Arg682 
does not participate in the binding. Indeed, in our 3D model (Fig. 3A) Arg682 is not exposed on the 
same side compared to Lys686, Lys666 and Arg653. To better explain our experimental data, we 
generated an homology model of the RGL2-RBD/Ras complex taking the crystallographic structure 
of the RalGDS-RBD/Ras complex as reference (Fig. 3B). In the model it is evident that Arg682 is 
located far from the RGL2-90 active site (depicted in green) and in particular far from any residue of 
Ras. Thus, mutations at this site do not affect binding because of the lack of any type of interaction. 
These findings indicate that, like the other RalGDS family members, the residues in the RGL2-RBD 
that mediate binding to Ras proteins are located at sites that correspond to those that mediate the 
interaction of Raf with Ras (in the Raf-binding domain) [18,28,30]. The correlation exists despite the 
fact that the RGL2- and Raf-Ras binding domains lack extensive aminoacid sequence similarity.  
In contrast, the substitution of the negatively charged Asp690 with Ala (RGL2(D690A)) increased 
the binding affinity toward H-Ras compared to native RGL2. A previous study of the interaction of 
Ras with the RBD domain of RalGDS family members showed that the negative charge of Asp820 in 
RalGDS-RBD exerts a repulsion effect with Glu31 residue in Ras [31]; this putative electrostatic 
repulsion is conserved in the Ras-RGL interaction and involves the same residue in Ras and Glu689 
in RGL-RBD, corresponding to Asp820 in RalGDS [28]. Here, we demonstrate that this effect is also 
conserved in the Ras-RGL2 interaction between H-Ras Glu31 and RGL2 Asp690. As Rap1b has a 
Lys in position 31 instead of a Glu, it can be expected that D690 of RGL2 and K31 of Rap would 
have a salt-bridge interaction and then the D690 mutation would cause decreased binding to Rap. 
However, this hypothesis is not supported by our experimental data, as the interaction of RGL2 with 
Rap1b was not affected by substitution of Asp690 with Ala (see table 1). Thus, it is possible that the 
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D690A mutation, although potentially able to affect a putative salt-bridge interaction, does not 
interfere sufficiently with the strength of the RGL2-RBD/Rap1b interaction to cause decreased 
binding. 
Substitution of Tyr719 with Ala had no effect on the interaction between RGL2-RBD and 
Ras/Rap1b, indicating that Tyr 719 does not directly participate in the interaction between RGL2 and 
Rap or Ras. Tyr 719 is located in the C-terminal region of the RGL2-RBD, a region with many 
conserved residues and important for the interaction because its deletion abrogated the binding to 
both Ras and Rap in vivo (Fig. 2B). Previous studies of the three-dimensional structure of RalGDS, 
RGL and Rlf [14-16] demonstrated that the RBD C-terminal region strongly contributes to the 
domain folding due to the hydrophobic interactions between its residues. Sequence alignment of the 
RGL2 RBD with that of RalGDS showed that 14 of the 15 residues that form the hydrophobic core in 
RalGDS are conserved in RGL2 (Ile652, Val654, Ile668, Val670, Ala676, Val679, Ile680, Leu699, 
Ile711, Val717, Phe718, Ala720, Phe728 and Leu730, see Fig 1B). Most of these residues belong to 
the consensus hydrophobic residues in ubiquitin and all RA (Ras Associating) domain sequences 
[17,18,32]. The almost total homology between RGL2 and RalGDS that we found at the level of 
residues that form the hydrophobic core, when considered with our experimental results, support the 
hypothesis that the C-terminal region plays a role in stabilizing the active binding conformation of 
RGL2-RBD. On the basis of our 3D model of RGL2, the C-terminus does not directly participate in 
the interaction, but its presence may be a determinant for the proper folding of the β1, β2 and α1 
domains that contain critical residues for the interactions. 
Previous work showed that the Ras effector domain (spanning between residue 30 and residue 40) 
was essential for its interaction with Raf-1 [33,34]; Rap1b has a 50% sequence homology with Ras, 
and the sequence of its effector domain is identical to that of the Ras effector domain. To further 
examine the interaction between RGL2-RBD and H-Ras and Rap1b, we studied several effector 
domain mutants. As shown in Table 2, wild type RGL2-RBD (WT) interacted with wild type H-Ras 
and Rap1b but not with the two effector domain mutants H-Ras(T35A) and Rap1b(T35A). A second 
effector domain mutation in Rap1b, E37G, did not abrogate the interaction with RGL2-RBD. RGL2-
RBD(K686A) did not interact with H-Ras and Rap1b mutants. The interaction of RGL2-RBD with 
Rap1b(E37G) appeared to be stronger when Asp690 is substituted by Ala. Based on the crystal 
structure of the Ras/RalGDS-RBD complex, Thr35 of Ras is involved in the interaction with 
RalGDS-RBD [28]. We showed that Thr35 in the effector domains of H-Ras and Rap1b plays a role 
in the binding with RGL2. The second effector domain mutation in Rap1b (E37G) did not affect the 
interaction of the protein with RGL2-RBD. This later result is consistent with findings that these 
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mutations define different functions of the effector loop. Glu37 has been demonstrated to be 
important for the interaction of Rap with Raf [35]. The increase of binding affinity between 
Rap1b(E37G) and RGL2(D690A) in the semiquantitative β-galactosidase assay may indicate the 
existence of a repulsive effect in native proteins between Glu37 (in Rap1b) and Asp690 (in RGL2) 
that is abrogated by substitution with two small and apolar residues (Gly in Rap1b and Ala in RGL2). 
 
Analysis of GEF activity of RGL2 – RGL2 possesses a N-terminal domain which has significant 
homology with CDC25, an exchange factor for Ras. It has been previously shown that Rlf functions 
as an exchange factor both for RalA and RalB, but not for H-Ras [20]. In addition, Shao et al. 
demonstrated that in RGL3 the Ral-GEF activity is mediated by a N-terminal 518 aminoacids region 
of the protein [8]. To determine the GEF activity of RGL2 toward Ras, Rap and Ral proteins, we 
employed an in vitro nucleotide exchange assay. Two members of the Rho family were also used in 
the assay to evaluate if RGL2 could be involved in crosstalk between Ras and Rho proteins [36]. 
Based on the Shao study, we first generated a 518 aminoacid N-terminal fragment of RGL2, 
RGL2(1-518), containing the CDC25 homology domain, but not the RBD domain, and evaluated its 
GEF activity for H-Ras, RalA, Rap1b, Rac1 and RhoA. As shown in Fig.4 A, RGL2(1-518) was able 
to stimulate the dissociation of [3H]GDP from RalA but not from the other proteins used in the assay. 
Sequence alignment of RGL2(1-518) with CDC25 (Fig.5) showed that the region of RGL2 
homologous to CDC25 spans between 92 and 512 residues. In order to see if this region was 
sufficient for the GEF activity of RGL2, we produced a deletion mutant of RGL2(1-518), RGL2(83-
518), containing the CDC25 homology region flanked by very short non homologous fragments. As 
showed in Fig.4B, the 83-518 fragment of RGL2 maintained the GEF activity toward RalA. 
Comparison to CDC25 permitted us to define in this fragment two regions of RGL2, 92-140 and 243-
512, corresponding to the REM motif and to the core catalytic domain  of CDC25, respectively (see 
Fig. 5). Both regions are required for exchange factors activity. Based on the crystal structure of 
Sos1, the REM motif itself does not have catalytic activity, but plays a key role in stabilizing the 
large helical hairpin structure that pries open the GTP-binding pocket [10].   
 
Phosphorylation analysis - It has been reported that RalGDS is phosphorylated in vitro and in intact 
cells by PKA on serine residues [2], but this phosphorylation has been reported to affect neither its 
interaction with Ras nor its GDS activity for Ralp24 [37]. RGL can be phosphorylated by PKA in 
vitro, but its phosphorylation does not affect its binding to Ras p21 and Rap1 [38]. Thus, the 
physiological significance of the phosphorylation of the two RalGDS proteins by PKA still remains 
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to be clarified. On the other hand, determining if  RalGDS proteins contain regulatory regions and 
how they function in vivo might provide insight into signaling through this family of proteins. 
Analysis of the RGL2 primary structure by using the software NetPhos 2.0 
(http://www.cbs.dtu.dk/services/NetPhos/) revealed a number of Ser residues as putative sites for 
phosphorylation. Among those with a higher score to be phosphorylated, only Ser737, corresponding 
to Ser738 in Rlf, constituted a potential PKA site. This sequence is located at the end of the RBD 
domain; this location is unique for RGL2 and its orthologue Rlf as the other RalGDS proteins do not 
have PKA phosphorylation sites in the same region. This so far appears to be the only significant 
difference between RGL2/Rlf and the other members of the RalGDS family and could indicate a 
peculiar mechanism of regulation of RGL2 by PKA. 
In order to determine if RGL2-RBD is a PKA substrate we mixed the catalytic subunit of PKA, the 
GST-deletion mutant fusion proteins RGL2(262-777) or RGL2(681-777) and [γ-32P]ATP. Samples 
were electrophoresed and subjected to autoradiography. Fig.6A shows that the RGL2(681-777) 
mutant, containing the Ras Binding Domain, as well as the longer RGL2(262-777) mutant, were both 
PKA substrates. The stoichiometry of phosphate transfer was approximatively one to one as 
determined from the specific radioactivity of radiolabeled bands. To prove that Ser737 is a 
phosphorylation site by PKA, the C-terminal fragment RGL2(544-777) was mutated at Ser737 and 
then phosphorylated with the catalytic subunit of PKA. As shown in Fig.6B, only the native 
RGL2(544-777) but not the mutant lacking Ser737 is a substrate for PKA. 
To examine the effect of the phosphorylation of RGL2 by PKA on its ability to bind H-Ras and 
Rap1b, RGL2(544-777) was incubated with the catalytic subunit of PKA in the presence of ATP. 
Phosphorylation was verified by SDS-PAGE and staining with a specific phosphoprotein stain (not 
shown). The ability of phosphorylated RGL2 to bind the activated form of H-Ras and Rap1b was 
compared to that of unphosphorylated RGL2 by using an ELISA format binding assay. As reported in 
Fig.7, phosphorylation of RGL2 by PKA significantly reduced the ability of RGL2(544-777) to 
complex both with H-Ras and Rap1b.  
In this work we showed that the C-terminal end of RGL2-RBD, where the site of PKA 
phosphorylation is located, does not directly participate in the interaction, but may be crucial for the 
proper folding of the RBD domain. If a charged group is introduced in such a region, it can be 
expected that this event might strongly affect the conformation of the entire domain, thus resulting in 
a reduction of its ability to bind Rap and Ras. 
To verify if phosphorylation of RGL2 by PKA occurs in intact mammalian cells as well, we 
overexpressed full length native and S737A RGL2 in HEK293 cells as fusions with GFP and then 
stimulated cells with forskolin as described in the Experimental Section. GFP-RGL2 or GFP-
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RGL2S737A were finally immunoprecipitated from cell protein extracts and analyzed by SDS-PAGE 
followed by ®ProQ Diamond Staining to selectively stain phosphorylated proteins (Fig. 8A). 
Coomassie Brilliant Blue staining of the same gel (Fig.8B) and immunoblotting analysis of a control 
gel loaded with the same amount of samples (Fig.8C) were performed to evaluate relative amounts of 
GFP-RGL2 in the different lanes. Figure 8A shows that wild type RGL2 is phosphorylated in 
HEK293 cells (lane 2) and phosphorylation increases when cells are stimulated  by forskolin (lane 1). 
The S737A mutant is phosphorylated as well, but there was no significant difference between 
stimulated and unstimulated cells in the level of phosphorylation (lanes 3 and 4). These data indicate 
that RGL2 is also phosphorylated by PKA in mammalian cells, and that Ser737 is the target of this 
phosphorylation; in addition, other residues of RGL2 may be phosphorylated by kinases other than 
PKA.  
 
In summary, by combining mutagenesis analysis, in vivo and in vitro binding assays and homology 
modelling, we defined and characterized the minimal Ras/Rap binding domain of RGL2. This 
domain appears to be a fragment of 90 amino acids in the C-terminal part of the protein and includes 
the region of highest conservation between the RalGDS family members. The interaction with the 
effector domain of Ras and Rap is GTP-dependent and is mediated by a structural epitope conserved 
with Raf-1. 
Our findings further indicate that RGL2, like the other RalGDS protein, has the potentiality to 
mediate the Ras-depending activation of Ral functioning as a downstream effector for Ras and an 
upstream activator of Ral. Thus, RalGDS proteins share important structural and functional features: 
they are ubiquitously expressed, they are able to act as effectors, although with different affinity, for 
Ras and Ras-related proteins, and they function as guanine nucleotide exchange factors for Ral. At 
present, it is not clear whether these proteins are functionally redundant or if they have distinct 
physiological roles, and how Ras proteins may distinguish these different interactors. Previous 
studies provided evidence supporting the hypothesis that Ras proteins may distinguish different 
effectors by their phosphorylation by PKA [37]. 
In this work we showed for the first time that only RGL2 is phosphorylated both in vitro and in 
mammalian cells by PKA at Ser737 and that phosphorylation significantly reduces the ability of 
RGL2 to bind H-Ras and Rap1b. RGL2 and Rlf are unique in the RalGDS family in that they have a 
PKA site in the RBD. Thus, while all RalGDS proteins are able to bind Ras proteins, in the case of 
RGL2/Rlf, this interaction may be regulated by PKA phosphorylation. These results suggest that Ras 
proteins may distinguish between the different RalGDS family members by their phosphorylation by 
PKA and support the hypothesis that this could be a general mechanism used by Ras to distinguish 
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the different effectors. On the basis of our results in mammalian cells and structure analysis, we 
cannot exclude the possibility that other PKA-independent phosphorylation events may occur and 
may be involved in controlling other features of RGL2 signaling such as its intracellular localization 
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FIGURE LEGENDS 
Fig. 1: The RalGDS proteins sequence 
(A) Domain structure of RalGDS proteins. (B) Sequence alignment of the C-terminal region 
of RalGDS proteins containing the relative RBDs: RalGDS (rat, 767-867; mouse, 724-824 
[2], human, 786-886 [4]), RGL (mouse, 634-736 [5]; human (634-736) [39], Rlf (635-737) 
[6], RGL2 (634-736) [7], and RGL3 (mouse, 596-697 [8]; human, 600-701 [9]). Sequence 
alignment was performed using the ClustalW program. Conserved residues are shaded in 
grey. 
 
Fig. 2: Deletion analysis of RGL2-RBD 
(A) Schematic representation of RGL2 deletion mutants used in this work. Black regions 
indicate conserved residues. (B) Results of the two-hybrid assay. cDNAs encoding the 
different fragments were fused in-frame with the GAL4 activation domain in pGAD424 
vector. The different constructs were cotransformed into HF7c yeast strain together with 
pGBT9 vector containing wild type (WT) or mutated Rap1 and H-Ras. Protein-protein 
interaction was assayed by the ability of transformants to grow in minimal medium lacking 
His. His+ transformants were assayed for β-galactosidase activity after 5 days of growth. 
aSemiquantitative determination of β-galactosidase activity of the His+ colonies. ++++ 
indicates blue staining detected within 1 hour, +++ indicates blue staining detected after 2 
hours, ++ indicates blue staining detected after 3-4 hours, + indicates blue staining detected 
after 5-6 hours, and – indicates no blue staining after 8 hours. The results were obtained three 
times in independent experiments. (C) Binding of different GST-RGL2 fusion proteins to H-
Ras in the ELISA format assay. The procedure is detailed in the Experimental section. 
Gpp(NH)p was added to the incubation buffers used in the assay to a final concentration of 
50 µM to prevent significant hydrolysis of GTP during the time course of the assay. Binding 
curves were generated by serially varying the concentration of the different RGL2 fragments 
while maintaining the Ras amount at 50 pmol/well. Recombinant GST was used as test 
protein in a negative control assay and determined the background binding of the assay. 
Protein-protein interaction was detected by using anti-GST antibody (1:3000 dilution) and 
anti-goat IgG-peroxidase conjugate antibody (1:25000 dilution). Absorbance values are 
plotted as a function of the test protein concentration. GST-RGL2(647-736),                 ; GST-
RGL2(677-736),                  ; GST-RGL2(647-706),                   ; GST,                 . 
The data shown are representative of three separate assays performed in triplicate. 
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Fig. 3: RGL2-RBD structure and Ras binding 
(A) RGL2-RBD three-dimensional structure. Ribbon diagram of the tertiary fold of RGL2 
(647-736) where the five β-strands are in pink and the two α-helices are in yellow [23]. The 
side chains of the residues mutated in this work are shown in ball-and-stick. The different 
colors indicate the different effects of substitution with Ala in the interaction with Ras/Rap: 
green, abrogation; orange, decreasing; grey, increasing; blue: no effect. 
(B) Three-dimensional structure of the RGL2-RBD/Ras complex. To build the RGL2-
RBD/Ras complex model, the crystallographical structure of the RalGDS-RBD/Ras complex 
(pdb ID 1LFD) was used as reference. The RGL2-RBD structure was fitted on the RalGDS 
structure using all the mainchain atoms. Fitting procedures and picture preparation were done 
using MolMol software [40]. 
Ras protein (grey), RGL2 residues involved in the interaction (green) and Arg682 (blue) are 
represented in CPK. 
 
Fig. 4: In vitro guanine nucleotide exchange factor activity of RGL2 for different small 
GTPases 
A. GEF activity of RGL2(1-518) for H-Ras, RalA, Rap1b, Rac1 and RhoA. 
H-Ras,              ; H-Ras + RGL2(1-518),              ; RalA,               ; 
RalA + RGL2(1-518),                ; Rap1b,             ; Rap1b + RGL2(1-518),               ; 
Rac1,               ; Rac1 + RGL2(1-518),               ; RhoA,       X     ; 
RhoA + RGL2(1-518),                . 
B. GEF activity of RGL2(83-518) for RalA. 
RalA,               ; RalA + RGL2(83-518),               .  
The guanine nucleotide exchange assay was performed as described in the Experimental 
section. Values are expressed as the percentage of the zero time point which was arbitrarily 
set at 100. Each value is the average of triplicate incubations and is representative of three 
separate experiments.  
  
Fig. 5 : Sequence alignment of RGL2 and CDC25 
The N-terminal 518 aminoacids of RGL2 and CDC25 were aligned using the ClustalW 
program. Conserved residues are shaded with black. The core catalytic domain of CDC25  is 
underlined with a continuous line; the REM domain is underlined with a dotted line.  
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Fig. 6: In vitro phosphorylation of RGL2-RBD 
After phosphorylation by PKA, GST-fused RGL2 mutants and GST were analyzed by SDS-
PAGE on 12.5% (A) or 12% (B) gels followed by autoradiography. (A) Lane #1- GST-
RGL2(262-777); Lane #2- GST-RGL2(681-777); Lane #3- GST negative control. (B) Lane 
#1- GST-RGL2(544-777)S737A; Lane#2- GST-RGL2(544-777). Molecular mass is indicated 
in kDa on the left of the figure. 
 
Fig. 7: Effect of the phosphorylation of RGL2 on its binding to H-Ras and Rap1b 
The unphosphorylated (GST-RGL2(544-777)) or phosphorylated (pGST-RGL2(544-777)) 
form of RGL2 and GST were used as test proteins in an ELISA format in vitro binding assay 
to evaluate their interaction with H-Ras(G12V) and Rap1b (G12V). 
Rap1b/GST-RGL2,                  ; Rap1b/pGST-RGL2,                  ;  
H-Ras/GST-RGL2,                  ; H-Ras/pGST-RGL2,                  ; H-Ras/GST,        
The procedure of this experiment is detailed in the Experimental section and in Figure 1C. 
The results shown are representative of three independent experiments performed in 
triplicate. 
 
Fig. 8: Phosphorylation of RGL2 in HEK293 cells 
Cells were transfected with pEGFP-RGL2 or pEGFP-RGL2S737A and treated with forskolin 
as described in the Experimental section. GFP fusions of  wild-type RGL2 and the S737A 
mutant were immunoprecipitated from cell lysates and then analyzed by SDS-PAGE 
followed by phosphoprotein specific ProQ staining (A), Coomassie Brilliant Blue Staining 
(B), or immunoblotting analysis with anti-GFP antibody (C). 
UT: untrasfected cells.  
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Table 1  
Mutation analysis of the interaction of RGL2-RBD and Rap/Ras 
Wild type Rap1b and H-Ras fused in pGBT9 were used to cotransform HF7c yeast strain 
along with different mutants of RGL2(647-736), prepared as described in the Experimental 




 β-galactosidase activity 
 H-Ras Rap1b 
Wild Type +++ ++ 
R653A - - 
Y665A + + 
K666A - - 
R682A +++ +++ 
K686A - - 
N687A + + 
D690A ++++ ++ 
Y719A ++ + 
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Double mutant analysis of the interaction of RGL2-RBD and Rap/Ras 
Wild type Rap1b and H-Ras and their mutants on the effector domain fused in pGBT9 were 
cotransformed into HF7c together with wild type and two mutants of RGL2-RBD. β-
galactosidase activity of the His+ colonies was evaluated as reported in the legend to Fig.2B. 
 
 
 β-galactosidase activity 
 WT K686A D690A 
H-Ras(WT) +++ - ++++ 
H-Ras(T35A) - - - 
Rap1b(WT) ++ - ++ 
Rap1b(T35A) - - - 
Rap1b(E37G) + - ++++ 
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